Expanding Biologicals Through In-House R&D, Partnerships and M&A
FMC Corporation's world-class biologicals business was initially built through two strategic transactions in 2013. These include the acquisition of the Center for Agricultural and Environmental Biosolutions (CAEB) assets and the signing of a global strategic alliance with Chr. Hansen, a global bioscience company. Together these initiatives helped create a robust biological platform that complements the traditional strengths of a synthetic crop protection portfolio.
Since that time FMC has invested significantly in the continued development of novel, differentiated biological products through its partnership with Chr. Hansen as well as through investment in FMC's European Innovation Center (EIC) located in Denmark.
FMC also has commercial distribution partnerships in place with Cytozyme and Marrone Bio in Latin America, and Certis in North America for products that are complementary to our portfolio.